Thompson Siegel & Walmsley’s Avadel Pharmaceuticals AVDL Stock Holding History

Thompson Siegel & Walmsley’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-51,550	Closed	-$629K	–	695
2015 Q4	$629K	Buy	51,550 +17,300	+51%	+$270K	0.01%	305
2015 Q3	$559K	Buy	34,250 +27,450	+404%	+$605K	0.01%	319
2015 Q2	$144K	Buy	+6,800	New	+$122K	﹤0.01%	398
2015 Q1	–	Sell	-16,091	Closed	-$276K	–	691
2014 Q4	$276K	Sell	16,091 -33,409	-67%	-$477K	0.01%	371
2014 Q3	$708K	Sell	49,500 -2,200	-4%	-$31.6K	0.01%	295
2014 Q2	$776K	Buy	51,700 +39,300	+317%	+$474K	0.02%	297
2014 Q1	$166K	Buy	+12,400	New	+$133K	﹤0.01%	395

Other funds holding AVDL

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return

FPC

Falcon Point Capital San Francisco, California $11.9M AUM 55.76% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

Thompson Siegel & Walmsley's AVDL Position: Q1 2016 in Review

Thompson Siegel & Walmsley sold out of Avadel Pharmaceuticals (AVDL) in Q1 2016, closing a stake of 51,550 shares — an estimated $629K sold.

Thompson Siegel & Walmsley first reported a position in AVDL in Q1 2014 and held it in 7 quarters. The position peaked at $776K in Q2 2014. 81 funds tracked by Wall St. Rank hold AVDL as of Q1 2016.

Thompson Siegel & Walmsley reported no remaining Avadel Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Thompson Siegel & Walmsley sold 51,550 Avadel Pharmaceuticals shares in Q1 2016, an estimated $629K.
Thompson Siegel & Walmsley first reported a position in Avadel Pharmaceuticals in Q1 2014 and held it in 7 quarters.
Thompson Siegel & Walmsley's Avadel Pharmaceuticals position peaked at $776K in Q2 2014.
81 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2016.

Based on Thompson Siegel & Walmsley's 13F filing for Q1 2016, filed 10 May 2016.